Allergen Specific Sublingual Immunotherapy (Acarizax, Grazax and Itulazax) in adults(332 KB) - Shared care agreement
Date added: 6th Sep 2024
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
Aspirin | Yellow | Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics |
*on advice of clinical genetics Patient weight <75kg: 150mg daily Patient weight >75kg: 300mg daily |
Asprin (UPDATED) | Yellow | Lynch syndrome cancer risk reduction |
Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics |
AZATHIOPRINE | Orange | Rheumatological disease | |
Bismuth, Metronidazole & Tetracycline ( Pylera) (NEW) | Green | Eradication of H. Pylori for patients with penicillin allergy already exposed to clarithromycin |
Use in line with local antimicrobial guidelines. |
Denosumab (Xgeva) | Red | Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min) | |
Estradiol & Medroxyprogesterone (Tridestra) (NEW) | Green | Hormone replacement therapy | |
Estradiol & Norethisterone (Trisequens) (NEW) | Green | Hormone replacement therapy | |
ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) (UPDATED) | Yellow | For treating moderate to severe symptoms of uterine fibroids in adults of reproductive age. |
Treatment for 6-12 months at the direction of specialist team. In line with NICE TA832 |
Finerenone | Green | Stage 3 and 4 chronic kidney disease associated with diabetes |
For treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults in line with NICE TA877. Use in line with the CKD Pathway. |
Lebrikizumab (NEW) | Red | For treating moderate to severe atopic dermatitis in people 12 years and over | |
LEFLUNOMIDE (UPDATED) | Orange | Rheumatological disease | |
METHOTREXATE Oral (UPDATED) | Orange | Rheumatological disease |
Full SCA Request form Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied. |
Nephrotrans (UPDATED) | Yellow | metabolic acidosis in chronic kidney disease |
Treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment only (limited use as a 2nd line option for patients who cannot tolerate the standard capsules e.g. due to bloating).’ To be initiated by renal team only. |
PENICILLAMINE | Orange | Rheumatoid arthritis | |
SULFASALAZINE | Orange | Rheumatological disease | |
Tenecteplase (NEW) | Red | For treating acute ischaemic stroke | |
Trihexyphenidyl | Green | Parkinson, Drug-induced extrapyramidal symptoms, Dystonia | |
Varenicline Tartrate (Champix) | Grey | Smoking cessation in adults |
Recent documents from LLR APC and TAS
Date added: 6th Sep 2024
Date added: 6th Sep 2024
Date added: 6th Sep 2024
Version 1
Date added: 4th Sep 2024
Updated August 2024
Date added: 15th Nov 2019
Version 7 uploaded September 2024
Date added: 12th Mar 2019
Version 2.0 Uploaded August 2024
Date added: 21st Jan 2016
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more